Brian Naftulin
Urology · Truckee, CANPI 1407977531
Payments from drug & device makers
Across 144 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$886
- Endo Pharmaceuticals Inc.$330
- AbbVie$317
- Pfizer$228
- Myriad Genetic Laboratories, Inc.$151
- Coloplast$138
- plus $460 from 13 others
What the payments were for
- Food & beverage$2,48199%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 64 | $886 |
| Endo Pharmaceuticals Inc. | 21 | $330 |
| AbbVie(2 entities) | 17 | $317 |
| Pfizer | 12 | $228 |
| Myriad Genetic Laboratories, Inc. | 5 | $151 |
| Coloplast | 6 | $138 |
| Laborie Medical Technologies Corp. | 2 | $79 |
| Teleflex LLC | 3 | $74 |
| Boston Scientific | 2 | $53 |
| Johnson & Johnson | 3 | $40 |
| Mindray DS USA, Inc. | 1 | $34 |
| Convatec Inc. | 1 | $27 |
| Accord Healthcare, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Bayer | 1 | $24 |
| Antares Pharma, Inc. | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Myovant Sciences Inc. | 1 | $18 |
| Dentsply IH AB | 1 | $17 |
How this compares
$2,511 in reported general payments places this provider in the 45th percentile of 1,324 urology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 17 | $18,095 |
| GemtesaVibegron | 16 | $15,516 |
| Trospium Chloride ErTrospium Chloride | 17 | $3,964 |
| Tamsulosin Hcl | 148 | $3,547 |
| Solifenacin Succinate | 48 | $1,259 |
| Testosterone | 23 | $1,186 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 40 | $517 |
| Finasteride | 25 | $288 |
| Cephalexin | 14 | $144 |
| Ciprofloxacin Hcl | 48 | $123 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $115 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $886 | $18,09517 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $15,51616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,324 urology providers in California.
Other urology in Truckee
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.